Stereotactic Ablative Radiotherapy achieves better overall survival than surgery for early lung cancer
Patients with operable stage I non-small cell lung cancer (NSCLC) could
achieve better overall survival rates if treated with Stereotactic
Ablative Radiotherapy (SABR) rather than the current standard of care -
invasive surgery - according to research from a phase III randomized
international study from The University of Texas MD Anderson Cancer Center.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Study | Texas University